Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2024-08, Vol.86 (2), p.183-184
Hauptverfasser:	Drake, Marcus J., Birder, Lori A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Clinical Trials, Phase III as Topic Humans Time Factors Treatment Outcome Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urologic Neoplasms - drug therapy Urologic Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!